Posted by Michael Wonder on 17 Nov 2020
UCB’s Vimpat (lacosamide) now approved by FDA in U.S. for primary generalised tonic-clonic seizures and expanded paediatric use for people living with epilepsy
17 November 2020 - All three Vimpat formulations, including injection for intravenous use, are now indicated for the treatment of partial-onset seizures and as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in patients four years of age and older.
UCB today announced that the U.S. FDA has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in patients four years of age and older and VIMPAT injection for intravenous use in children four years of age and older.
